It should be enough if responsible and qualified clinicians have found that the drug produces the claimed effect…FDA should not be the arbiter of such conflicting views which necessarily involve large elements of subjective opinion by qualified scientists. Otherwise, we face the serious danger to medical progress inherent in a central authority where conflicting viewpoints in medicine will be indirectly resolved, as they are under a totalitarian system, and we run the very grave risk of recasting our system in a sterile, foreign mold…
Theodore Klumpp, member of the board of directors of the Pharmaceutical Manufacturers Association (PMA) and a former FDA medical director, testifies against the Kefauver bill. From the June 19-22, 1962, House Committee on Interstate and Foreign Commerce hearings.
